Horizon is one of the fastest growing biotechnology companies in Europe with a staff of more than 100 people spread across scientific, operations and commercial functions and accommodated within a 20,000 sq. ft. state-of-art facility in Cambridge, UK. The company has a customer base comprising many hundreds of academic research institutes, biotechnology, diagnostic and pharmaceutical companies.

Horizon is a privately owned company funded by a blue chip investor base including: MVM Life Sciences LLP, DFJ Esprit LLP, Roche Venture Fund, Dr Jonathan Milner, Mr David Evans, Mr Peter Collins, Providence Investment Company Ltd and Mr David Cleevely. Horizon has raised approximately £15m since its Seed investment in March 2008 and achieved a 100 fold increase in valuation in the same period.

We aim to answer as many of your questions as we can in these pages, however if there is any further information you need please do contact us.

View our Board of Directors  

View our latest News